Ad is loading...
OPORF
Price
$0.37
Change
-$0.00 (-0.00%)
Updated
Oct 7 closing price
PMN
Price
$0.98
Change
-$0.01 (-1.01%)
Updated
Nov 15 closing price
117 days until earnings call
Ad is loading...

OPORF vs PMN

Header iconOPORF vs PMN Comparison
Open Charts OPORF vs PMNBanner chart's image
OPEN ORPHAN
Price$0.37
Change-$0.00 (-0.00%)
Volume$150
CapitalizationN/A
ProMIS Neurosciences
Price$0.98
Change-$0.01 (-1.01%)
Volume$30.71K
CapitalizationN/A
OPORF vs PMN Comparison Chart
Loading...
View a ticker or compare two or three
VS
OPORF vs. PMN commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OPORF is a Buy and PMN is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (OPORF: $0.37 vs. PMN: $0.98)
Brand notoriety: OPORF and PMN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OPORF: 32% vs. PMN: 41%
Market capitalization -- OPORF: $230.53M vs. PMN: $29.29M
OPORF [@Biotechnology] is valued at $230.53M. PMN’s [@Biotechnology] market capitalization is $29.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OPORF’s FA Score shows that 2 FA rating(s) are green whilePMN’s FA Score has 0 green FA rating(s).

  • OPORF’s FA Score: 2 green, 3 red.
  • PMN’s FA Score: 0 green, 5 red.
According to our system of comparison, OPORF is a better buy in the long-term than PMN.

Price Growth

OPORF (@Biotechnology) experienced а 0.00% price change this week, while PMN (@Biotechnology) price change was -8.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

PMN is expected to report earnings on Mar 14, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
OPORF($231M) has a higher market cap than PMN($29.3M). OPORF YTD gains are higher at: 145.503 vs. PMN (-14.783). OPORF has higher annual earnings (EBITDA): 14M vs. PMN (-11.95M). OPORF has higher revenues than PMN: OPORF (56M) vs PMN (0).
OPORFPMNOPORF / PMN
Capitalization231M29.3M788%
EBITDA14M-11.95M-117%
Gain YTD145.503-14.783-984%
P/E Ratio11.50N/A-
Revenue56M0-
Total CashN/A1.03M-
Total DebtN/A4.05M-
FUNDAMENTALS RATINGS
PMN: Fundamental Ratings
PMN
OUTLOOK RATING
1..100
96
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
84
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOLE14.73-0.08
-0.54%
Dole plc
BKR42.94-0.24
-0.56%
Baker Hughes Company
CVLT168.53-2.50
-1.46%
Commvault Systems
DUOT3.76-0.18
-4.57%
Duos Technologies Group
MRSN2.21-0.31
-12.30%
Mersana Therapeutics

OPORF and

Correlation & Price change

A.I.dvisor indicates that over the last year, OPORF has been loosely correlated with YMAB. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if OPORF jumps, then YMAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OPORF
1D Price
Change %
OPORF100%
N/A
YMAB - OPORF
34%
Loosely correlated
-3.88%
ENTX - OPORF
31%
Poorly correlated
-2.81%
PMN - OPORF
23%
Poorly correlated
-1.46%
EWTX - OPORF
6%
Poorly correlated
-4.35%
BCTX - OPORF
4%
Poorly correlated
N/A
More

PMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PMN has been loosely correlated with SYRE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PMN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMN
1D Price
Change %
PMN100%
-1.46%
SYRE - PMN
44%
Loosely correlated
-6.62%
BBIO - PMN
42%
Loosely correlated
-1.62%
ABOS - PMN
33%
Poorly correlated
-8.05%
LIXT - PMN
27%
Poorly correlated
+1.25%
ARGX - PMN
25%
Poorly correlated
-5.18%
More